SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
SAB Biotherapeutics, Inc.
NASDAQ:SABSHealthcare · Biotechnology
+3.72%$3.35
AH$3.35+0.00%vs close
Mkt Cap$304.8M
Float77.74M
O/S90.99M
Vol
$ Vol
RVOL
Inst Own75.2%
SI6.2%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income$13.27M
Total Assets$172.81M
Free Cash Flow-$45.71M
Debt & Equity
Debt 4%
Equity 96%
Preferred 0%
Total Debt$5.95M
Total Equity$151.49M
Preferred Stock$67
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:10Reverse splitJan 5, 202410 shares → 1
Balance Sheet Details
Assets$172.81M
Liabilities$21.32M
Accounts Receivable$947K
Accounts Payable$3.15M
Inventory$0
PP&E (Net)$19.4M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $1.32M | $2.24M | $23.9M | $60.88M | $55.24M | $3.44M |
| YoY Growth | - | -40.9% | -90.6% | -60.7% | 10.2% | 1504.8% | - |
| Cost of Revenue | $3.08M | $4.79M | $3.75M | $3.29M | $1.65M | $0 | $0 |
| Gross Profit | -$3.08M | -$3.47M | -$1.51M | $20.61M | $59.22M | $55.24M | $3.44M |
| Gross Margin | - | -262.4% | -67.3% | 86.2% | 97.3% | 100.0% | 100.0% |
| Research and Development | $34.35M | $30.16M | $16.52M | $36.44M | $57.18M | $27.91M | $8.02M |
| Selling, General, and Administrative | $14.6M | $9.28M | $23.8M | $16.38M | $17.09M | $6.77M | $4.1M |
| Other | -$3.08M | $0 | -$3.75M | -$3.29M | -$1.65M | $0 | -$1K |
| Total Operating Expenses | $45.87M | $39.44M | $36.57M | $49.53M | $72.62M | $34.68M | $12.12M |
| Operating Income (EBIT) | -$48.95M | -$42.91M | -$38.08M | -$28.92M | -$13.39M | $20.56M | -$8.67M |
| Operating Margin | - | -3244.9% | -1700.5% | -121.0% | -22.0% | 37.2% | -252.0% |
| Interest Expense | $241K | $318K | $315K | $302K | $294K | $469K | $428K |
| Interest Income | $1.43M | $1.29M | $585K | $71K | $23K | $26K | $113K |
| Other Income (Expense) | $62.23M | $8.81M | -$4.12M | $10.2M | -$3.75M | -$439K | -$313K |
| Income Before Tax (EBT) | $13.27M | -$34.11M | -$42.19M | -$18.72M | -$17.14M | $20.12M | -$8.99M |
| Income Tax Expense | $0 | $0 | $0 | $26K | $0 | $0 | $0 |
| Net Income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M | $20.12M | -$8.99M |
| Net Income Margin | - | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% | -261.1% |
| Supplementary Data | |||||||
| EPS | 0.22 | -3.68 | -7.64 | -4.31 | -6.30 | 7.45 | -0.22 |
| Diluted EPS | -0.79 | -3.68 | -7.64 | -4.31 | -6.30 | 7.45 | -0.22 |
| Weighted Average OS | 19.31M | 9.26M | 5.52M | 4.35M | 2.73M | 2.70M | 4.35M |
| EBITDA | $16.6M | -$28.99M | -$38.13M | -$15.12M | -$15.2M | $21.14M | -$8.23M |
| EBITDA Margin | - | -2192.5% | -1703.2% | -63.3% | -25.0% | 38.3% | -239.2% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $10.5M | $8.9M | $56.57M | $15.05M | $33.21M | $12.61M | $6.35M |
| Short-Term Investments | $86.09M | $11.86M | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $96.59M | $20.76M | $56.57M | $15.05M | $33.21M | $12.61M | $6.35M |
| Accounts Receivable | $947K | $55K | $0 | $5.56M | $8.01M | $20.57M | $2.82M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.51M | $2.98M | $0 | $0 | $6.34M | $0 | $0 |
| Total Current Assets | $101.05M | $23.79M | $58.91M | $22.1M | $50.19M | $34.46M | $9.29M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $19.4M | $19.92M | $24.68M | $28.34M | $30.95M | $22.08M | $8.71M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $46.89M | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $5.46M | $482K | $350K | $468K | -$1 | $0 | $0 |
| Total Long-Term Assets | $71.76M | $20.4M | $25.03M | $28.81M | $30.95M | $22.08M | $8.71M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $172.81M | $44.2M | $83.94M | $50.9M | $81.14M | $56.54M | $18M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $3.15M | $1.69M | $946K | $3.68M | $4.46M | $7.38M | $2.17M |
| Short-Term Debt | $951K | $276K | $1.05M | $773K | $1.8M | $539K | $1.39M |
| Current Income Tax Payable | $0 | $0 | $40K | $50K | $216K | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $1.32M | $0 | $100K | $100K | $0 |
| Other Current Liabilities | $1.55M | $0 | $4.49M | $8.1M | $8.7M | $1.17M | $249K |
| Total Current Liabilities | $10.68M | $7.98M | $10.81M | $14.99M | $26.46M | $11.06M | $4.62M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $542K | $0 | $172K | $53K |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $5.64M | $6.39M | $11.77M | $321K | $10.72M | $0 | $10M |
| Total Long-Term Liabilities | $10.63M | $10.25M | $15.83M | $4.85M | $16.14M | $6.47M | $15.69M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $21.32M | $18.23M | $26.64M | $19.85M | $42.59M | $17.53M | $20.31M |
| Stockholders' Equity | |||||||
| Preferred Stock | $67 | $5 | $5 | $0 | $0 | $2K | $1K |
| Common Stock | $5K | $935 | $929 | $5K | $4K | $4K | $4K |
| Retained Earnings | -$110.9M | -$124.17M | -$90.06M | -$47.87M | -$29.13M | -$11.98M | -$32.1M |
| Comprehensive Income & Other | $187K | -$135K | $26K | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $262.38M | $150.14M | $147.36M | $78.92M | $67.67M | $50.99M | $29.79M |
| Total Equity | $151.49M | $25.97M | $57.3M | $31.06M | $38.55M | $39.01M | -$2.31M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $172.81M | $44.2M | $83.94M | $50.9M | $81.14M | $56.54M | $18M |
| Supplementary Data | |||||||
| Total Debt | $5.95M | $4.67M | $5.91M | $5.93M | $8.52M | $8.13M | $7.64M |
| Net Debt | -$4.55M | -$4.23M | -$50.66M | -$9.12M | -$24.69M | -$4.48M | $1.29M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | $13.27M | -$34.11M | -$42.19M | -$18.74M | -$17.14M | $20.12M | -$8.99M |
| Depreciation & Amortization | $3.08M | $4.79M | $3.75M | $3.29M | $1.65M | $548K | $323K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $5.21M | $2.94M | $2.42M | $2.67M | $2.31M | $1.3M | $371K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$892K | -$55K | $5.56M | $2.45M | $12.56M | -$17.75M | -$2.56M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $1.48M | $923K | -$2.7M | -$779K | -$2.94M | $5.21M | $1.56M |
| Other Working Capital | -$4.28M | -$3.17M | -$529K | -$1.91M | $2.06M | $585K | $84K |
| Total Working Capital Change | -$3.69M | -$2.3M | $2.33M | -$238K | $11.68M | -$11.95M | -$923K |
| Other Non-Cash Items | -$62.66M | -$5.62M | $8.58M | -$10.45M | $3.48M | -$2K | $422 |
| Net Cash from Operating | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M | $10M | -$9.21M |
| Investing Activities | |||||||
| Capital Expenditures | -$933K | -$337K | -$197K | -$2.17M | -$10.94M | -$12.73M | -$609K |
| Acquisitions | $500 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$142.04M | -$37.45M | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $21.26M | $25.82M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $44K | $76K | $0 | $9K | $0 |
| Net Cash from Investing | -$121.71M | -$11.96M | -$153K | -$2.09M | -$10.94M | -$12.72M | -$609K |
| Financing Activities | |||||||
| Debt Repaid | $418K | $907K | $390K | $1.19M | -$1.54M | $918K | $623K |
| Common Stock Issuance | $168.73M | $20K | $0 | $7.68M | $7K | $9.9M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | -$5.52M | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$12K | -$286K | $59.66M | $77K | $34.34M | -$9.9M | $0 |
| Net Cash from Financing | $168.3M | -$1.17M | $66.77M | $1.05M | $35.89M | $8.98M | $3.68M |
| Forex Effect | -$213K | -$241K | $18K | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.6M | -$47.67M | $41.52M | -$24.5M | $26.93M | $6.26M | -$6.14M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$44.78M | -$34.29M | -$25.12M | -$23.46M | $1.99M | $10M | -$9.21M |
| Capital Expenditure | -$933K | -$337K | -$197K | -$2.17M | -$10.94M | -$12.73M | -$609K |
| Free Cash Flow | -$45.71M | -$34.63M | -$25.32M | -$25.63M | -$8.96M | -$2.73M | -$9.82M |
| Cash at Beginning | $8.9M | $56.57M | $15.05M | $39.55M | $12.61M | $6.35M | $12.49M |
| Cash at End | $10.5M | $8.9M | $56.57M | $15.05M | $39.55M | $12.61M | $6.35M |